MODULE 4

Patient Experience Data in action 

Discover how Patient Experience Data (PED) is applied in real-world settings.

Through practical examples from patient organisations, you’ll see how PED is planned, conducted, analysed, and transformed into meaningful evidence. The module wraps up with an expert interview exploring why PED is becoming essential in shaping today’s research, care, and policy.

What you are going to learn

From Insight to impact: applying PED 

Explore how PED is used in real life by patient organisations to make patient voices visible, credible, and actionable in healthcare and research.
You will move beyond theory to see how PED is translated into practice and how it can inform decisions, improve care, and strengthen advocacy.
  • Understand how different types of Patient Experience Data (PED)—including PROs, PROMs, qualitative approaches, and preference studies—are used in practice.
  • Explore how patient organisations design, conduct, and analyse PED studies in real-world settings.
  • Learn what makes PED meaningful, credible, and fit-for-purpose for different goals such as advocacy, research, and engagement with industry or policymakers.
  • Gain insight into practical challenges and lessons learned when working with PED, including feasibility, ethics, and use of digital tools.
  • Hear from an expert in an in‑depth interview on why PED is becoming increasingly critical across healthcare, research, and decision‑making today.

Self -paced

Take the whole course or select from the topics most relevant to you. 

Beginner - Intermediate 

This training is a valuable resource for patients,  professionals and advocates involved in healthcare decision-making.

Learn from experts

This course was developed through the collaboration of diverse stakeholders, including patient advocates, researchers, clinicians, representatives of HTA bodies, regulatory authorities, and industry professionals.

Detailed Module Contents

This WECAN Training Program on Patient Experience Data was initiated in 2023 as part of the WECAN Academy.
Funding for the module was administered by the European Patient Advocacy Institute (EPAI) gUG Germany and was obtained from industry and non-industry funders: including Biomarin, Bristol Myers Squibb, Boehringer Ingelheim, Rising Tide Foundation for Clinical Cancer Research, Roche, Servier, and Takeda. 
 The funders had no role in the course development.